Triple

T18763488
Position Surface form Disambiguated ID Type / Status
Subject Aegis Ashore (Romania) E458834 entity
Predicate partOf P40 FINISHED
Object European Phased Adaptive Approach NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: European Phased Adaptive Approach | Statement: [Aegis Ashore (Romania), partOf, European Phased Adaptive Approach]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: European Phased Adaptive Approach
Context triple: [Aegis Ashore (Romania), partOf, European Phased Adaptive Approach]
  • A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
    The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
  • B. ICH E8 General Considerations for Clinical Trials
    ICH E8 General Considerations for Clinical Trials is an international guideline that outlines fundamental principles and quality considerations for the design, conduct, and evaluation of clinical studies across all phases of drug development.
  • C. Conditional Marketing Authorization by European Medicines Agency
    Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
  • D. APHINITY trial
    The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
  • E. Clinical Practices of the University of Pennsylvania
    Clinical Practices of the University of Pennsylvania is the faculty practice plan and outpatient clinical arm of Penn Medicine, providing patient care across a wide range of specialties in collaboration with the University of Pennsylvania’s health system.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: European Phased Adaptive Approach
Target entity description: The European Phased Adaptive Approach is a U.S.-led NATO missile defense strategy for Europe that deploys increasingly advanced land- and sea-based interceptors and radars in successive phases to protect against ballistic missile threats.
  • A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
    The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
  • B. ICH E8 General Considerations for Clinical Trials
    ICH E8 General Considerations for Clinical Trials is an international guideline that outlines fundamental principles and quality considerations for the design, conduct, and evaluation of clinical studies across all phases of drug development.
  • C. Conditional Marketing Authorization by European Medicines Agency
    Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
  • D. APHINITY trial
    The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
  • E. Clinical Practices of the University of Pennsylvania
    Clinical Practices of the University of Pennsylvania is the faculty practice plan and outpatient clinical arm of Penn Medicine, providing patient care across a wide range of specialties in collaboration with the University of Pennsylvania’s health system.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d8d395dba0819087568404508590cb completed April 10, 2026, 10:40 a.m.
NER Named-entity recognition batch_69e58d80a954819083946dafc0c7af05 completed April 20, 2026, 2:20 a.m.
Created at: April 10, 2026, 11:52 a.m.